

A drug discovery bio-venture handling basic research to clinical development

This report is an English translation of part of the report issued on September 28, 2021.
For inquiries concerning the report, please contract info@stock-r.org

[4889 Renaissance Sector : Pharmaceutical]

Fiscal Year	Net sales (mn yen)	YoY (%)	Operating profit (mn yen)	YoY (%)	Ordinary profit (mn yen)	YoY (%)	Profit (mn yen)	YoY (%)	EPS (yen)	BPS (yen)	DPS (yen)
Mar. 2020	72	-	-183	-	-183	-	-184	-	-18.8	63.3	0.0
Mar. 2021	209	2.9	-86	-	-90	-	-100	-	-10.2	57.0	0.0
Mar. 2022 f	122	-41.7	-395	-	-399	-	-400	-	-36.0	-	0.0

Note: Non-consolidated basis. Figures are the company's forecasts.

It conducted 1-to-300 stock split on June 1, 2020. Per share indices are adjusted retroactively.

Aims to Discover Drugs by Utilizing Various Modalities

Renaissance is a bio-venture that seeks to create new medical care utilizing pharmaceuticals, medical devices, artificial intelligence (AI) solutions and various other modalities.

The World Health Organization (WHO) defines cancers, diabetes, respiratory diseases, and cardiovascular diseases as noncommunicable diseases (NCDs), and the company targets these NCDs as its fields for developing drugs. In addition, the company also grapples with female illnesses and childhood illnesses including their mental healthcare as well as lung disorders resulting from the novel coronavirus (COVID-19) infection.

At the time of its establishment in February 2000, the company centered on development of small molecule drugs including the PAI-1 inhibitor that has the possibility of treating a series of age-related diseases, but with requests from research and medical institutions as well as the need to solve problems in medical settings, the company also added medical devices and AI solutions to its modalities.

The company conducts research and development of the concepts and seeds, which regard various modalities, discovered by universities and other research institutions in Japan and abroad. It thoroughly covers everything from basic research to investigator-initiated clinical trials, in which investigators themselves plan and devise clinical trials as well as execute after submitting notifications of clinical trial protocols. The company's business model is to license out development rights, manufacturing rights, distribution rights, etc. of its products to major pharmaceutical companies after completion of the phase II clinical trial considering that this increases the possibility of commercialization, and gains upfront payments upon contract conclusion, milestone payments according to the development status, royalty payments as a certain percentage of the sales after the products are placed on the market, and sales milestone payments paid upon achievement of each sales target.

Renaissance (4889 TSE Mothers) - - - - - October 1,2021**Financial Statements**

Statement of income	Fiscal Year	Mar.2020		Mar.2021		Three months to Jun. 2021	
		(mn yen)	(%)	(mn yen)	(%)	(mn yen)	(%)
Operating revenue		72	100.0	209	100.0	31	100.0
Cost of operating		20	27.8	29	14.3	2	6.4
Gross profit		52	72.2	179	85.7	29	93.6
Operating expense		235	326.5	265	126.8	58	189.9
Operating profit		-183	-	-86	-	-29	-
Non-operating income		0	-	2	-	-	-
Non-operating expenses		0	-	7	-	2	-
Ordinary profit		-183	-	-90	-	-32	-
Extraordinary income		-	-	-	-	-	-
Extraordinary loss		-	-	9	4.3	-	-
Profit before income taxes		-183	-	-99	-	-32	-
Net profit		-184	-	-100	-	-32	-

Balance sheet	Fiscal Year	Mar.2020		Mar.2021		Jun. 2021	
		(mn yen)	(%)	(mn yen)	(%)	(mn yen)	(%)
Current assets		987	97.5	1,042	97.8	1,233	98.2
Cash and deposits		980	96.9	1,025	96.2	1,203	95.8
Accounts receivable		-	-	-	-	11	0.9
Prepaid expenses		3	0.3	7	0.7	9	0.7
Non-current assets		24	2.5	23	2.2	23	1.8
Property, plant and equipment		3	0.3	3	0.3	3	0.3
Intangible assets		15	1.5	13	1.2	12	1.0
Investments and other assets		6	0.6	7	0.7	7	0.6
Total assets		1,012	100.0	1,066	100.0	1,256	100.0
Current liabilities		11	1.1	29	2.8	12	1.0
Non-current liabilities		4	0.4	26	2.5	9	0.7
Accrued expenses		3	0.3	2	0.2	2	0.2
Income taxes payable		3	0.3	0	0.0	0	0.0
Non-current liabilities		380	37.5	475	44.6	475	37.9
Long-term borrowings		380	37.5	475	44.6	475	37.9
Net assets		621	61.4	561	52.6	768	61.2
Owners' equity		621	61.4	561	52.6	768	61.2

Statement of cash flows	Fiscal Year	Mar.2020	Mar.2021
		(mn yen)	(mn yen)
Cash flows from operating activities		-178	-89
Depreciation		3	2
Cash flows from investing activities		-380	-1
Cash flows from financing activities		380	135
Dividends paid		-	-
Net increase in cash and cash equivalents		-179	44
Cash and cash equivalents		600	644

Note: Non-consolidated basis.

Source: Prepared by Stock Research Center based on the notifiable prospectus.

About Stock Research Center

Stock Research Center is engaged in the preparation of analyst reports, mainly on companies that are not sufficiently covered by analysts, based on a neutral perspective, and broadly disclose the reports to the public with an aim to revitalize the stock market.

Note: Reports prepared by Stock Research Center are created in reference to the Ministry of Economy, Trade and Industry's Guidance for Integrated Corporate Disclosure and Company-Investor Dialogues for Collaborative Value Creation.



■Supporting Members

Tokyo Stock Exchange, Inc.
Nomura Securities Co., Ltd.
Ernst & Young ShinNihon LLC
Deloitte Touche Tohmatsu LLC
H.S. Securities Co., Ltd.
TAKARA PRINTING CO., LTD.
A&A Partners

SMBC Nikko Securities Inc.
Mizuho Securities Co., Ltd.
ICMG Co., Ltd.
SBI SECURITIES Co., Ltd.
Ichiyoshi Securities Co., Ltd.
PRONEXUS INC.

Daiwa Securities Co. Ltd.
KPMG AZSA LLC
Grant Thornton Taiyo LLC
BDO Sanyu
Japan Securities Dealers Association
The Securities Analysts Association of Japan

Certification by Analysts

Analysts indicated in the reports certify that the content indicated in the report precisely reflects the personal opinions of the analysts on all securities and issuer companies discussed in the report. In addition, it is ensured that the opinions directly or indirectly indicated in the report will have no influence on the analyst's compensation in the past, present, and future upon writing the report.

Disclaimer

- The report is prepared by stock analysts affiliated with the Stock Research Center for the purpose of disclosure to a wide range of investors as reference information and not to recommend or solicit to buy or to sell any particular securities or financial instrument.
- The content and indication of the report is based on disclosed information available publicly and is prepared by adding necessary supplementary information gained through interviews by analysts. The writer of the report is, without exception, prohibited to use insider information, or to acquire such information. The information included in the report is believed to be precise and reliable, but its preciseness is not verified objectively. In addition, the report is not intended to comprehensively include all information required by investors.
- The information included in the report may become outdated due to changes in the financial market, economic environment, etc. There are risks that the prices of stocks featured directly or indirectly in the report will fall below the par value due to fluctuations in stock prices, changes in management/financial conditions of the issuers, fluctuations in exchange rates or interest rates, etc. Past performance does not imply or guarantee future performance.
- The opinions indicated in the report are subject to change without notice and the Stock Research Center has no obligation to update the information or opinions included in the report.
- The Stock Research Center does not bear any responsibility for any results, including direct losses, indirect losses, losses of profit and damages, suffered by investors due to using the report or relying on the report. Final investment decisions shall be made by investors themselves and the sole responsibility concerning the investment lies with the investors that viewed the report.
- The copyright of the report belongs to the Stock Research Center and it may not be copied, reproduced, quoted, etc. in any form without prior consent.